Welcome to our dedicated page for SS Innovations SEC filings (Ticker: SSII), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
SS Innovations International Inc. (Nasdaq: SSII) files reports and disclosures with the U.S. Securities and Exchange Commission as a registrant with common stock listed on The Nasdaq Stock Market LLC. These SEC filings provide detailed information about the company’s operations in surgical robotics, including its SSi Mantra surgical robotic system and SSi Mudra surgical instruments.
On this page, you can review SSII’s periodic and current reports, such as Form 10-Q quarterly reports and Form 8-K current reports. In its filings and related press releases, SS Innovations has discussed revenue from system sales, instrument sales, warranty sales, and lease income, as well as information about installations of the SSi Mantra system and the cumulative number of surgeries performed. Filings also reference clinical and regulatory milestones, including a human factors validation study for the SSi Mantra at Johns Hopkins Hospital and plans for a 510(k) premarket notification to the U.S. Food and Drug Administration.
SS Innovations’ Form 8-K filings frequently incorporate press releases as exhibits, covering topics such as financial results, telesurgery achievements using the SSi Mantra and the SSi Mantra Tele Surgeon Console, executive appointments, and participation in investor conferences. These documents also confirm that the company’s common stock trades under the symbol SSII and that it is incorporated in Florida with principal executive offices in Gurugram, Haryana, India.
Stock Titan’s SEC filings page for SSII is designed to surface these regulatory documents alongside AI-powered summaries that explain key points in plain language. Users can quickly scan new 8-Ks, 10-Qs, and other filings, and identify disclosures related to revenue composition, operating performance, regulatory progress for the SSi Mantra system, and other material events affecting SS Innovations International Inc.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava reported a bona fide gift of 246,000 shares of common stock on behalf of an affiliated entity. The shares were held indirectly through Sushruta Pvt. Ltd., in which he has a controlling interest.
After this gift transfer, the filing shows 109,595,767 shares of common stock still reported as owned indirectly. Because this was a gift with no sale proceeds and represents a small portion of the reported holdings, it reflects a non-market, estate or relationship-driven transfer rather than a trading decision.
SS Innovations International, Inc. filed an amendment to its annual report for the year ended December 31, 2025. The amendment adds Exhibit 97.1, a Clawback Policy, to the exhibits list and includes new Section 302 and 906 officer certifications. The company states the amendment does not change any previously reported financial results or other disclosures in the original annual report.
SS Innovations International, Inc. reported new regulatory approvals for its SSi Mantra surgical robotic system in Colombia, Oman, Sri Lanka and Kenya, expanding its addressable markets in Latin America, the Middle East, Africa and South Asia. The system now has regulatory clearance in eleven countries, including India and the United Arab Emirates. As of December 31, 2025, SSi Mantra’s installed base totaled 168 systems across ten countries, with 7,885 cumulative surgeries performed, including 390 cardiac procedures and 121 pediatric surgeries, plus more than 150 telesurgeries. The company also stated it anticipates U.S. FDA review of its 510(k) submission to be completed by mid‑2026 and believes it can obtain European Union CE marking in 2026.
SS Innovations International, Inc. chairman and CEO Sudhir Srivastava reported a bona fide gift of 10,000 shares of common stock. The shares were held indirectly through Sushruta Pvt. Ltd., in which he has a controlling interest. This was a transfer without sale proceeds, not an open-market trade. Following the gift, indirect holdings reported in this filing total 109,841,767 shares, indicating the transaction is small relative to his overall position.
SS Innovations International, Inc. reported that its SSi Mantra surgical robotic system has been approved for telesurgeries in Indonesia and the Philippines. The company highlighted that more than 150 cumulative telesurgeries have been successfully performed with SSi Mantra, primarily in India, underscoring growing real‑world use of its platform.
The update describes recent benchmarks, including 18 inter-hospital telesurgeries completed between two Indian cities in eight hours on February 14, 2026, and an earlier 12-hour telesurgery marathon with 24 procedures on December 23, 2025. SS Innovations also announced it will host the Global Multi-Specialty Robotic Surgery Conference 2026 in New Delhi from April 9-11, 2026, where over 20 live telesurgeries using SSi Mantra are planned.
SS Innovations International, Inc. director and 10% owner Frederic H. Moll bought 501,253 shares of common stock in an open-market purchase at $3.99 per share. After this transaction, he directly owned 10,775,485 common shares.
SS Innovations International director Timothy P. Adams increased his indirect stake by buying 300,000 common shares in an open-market transaction at $3.99 per share. The shares are held through the Adams Marriage Trust, which now owns 5,331,902 SSII shares for his benefit.
SS Innovations International, Inc. Chairman and CEO Sudhir Srivastava, through Sushruta Pvt. Ltd., made an open-market purchase of the company’s common stock. On March 6, 2026, Sushruta Pvt. Ltd. bought 498,753 shares at $4.01 per share, bringing its indirect holding to 109,851,767 shares.
SS Innovations International reported rapid growth for 2025, with revenue rising to $42.5M from $20.6M, driven mainly by higher SSi Mantra system, instrument, and warranty sales. Fourth quarter 2025 revenue reached $14.5M, up sharply from $8.1M, as installations and surgeries increased.
The company reduced its annual net loss to $12.1M from $19.2M, though operating cash flow was negative at $18.5M. Total assets grew to $74.2M and stockholders’ equity to $38.2M, supported by significant financing, including a post‑quarter private placement raising about $18.6M in gross proceeds.
Management highlighted strong adoption of the SSi Mantra in India, expansion into new geographies, and ongoing work toward U.S. FDA 510(k) review targeted for mid‑2026 and European Union CE marking. They anticipate continued strong growth in 2026 as more systems are deployed and robotic procedures scale.
SS Innovations International, Inc. files its annual report describing rapid expansion in surgical robotics focused on making robotic surgery more affordable, especially in India and other underserved markets. The company’s SSi Mantra system has received Indian CDSCO approval, ISO 13485 certification, and additional clearances in multiple countries.
As of December 31, 2025, SSi Mantra had 168 installed systems across 10 countries and was used in 7,885 procedures, most in general surgery and urology, with more than 120 telesurgeries completed over distances up to thousands of miles. On March 6, 2026, the company completed a private placement of 5,774,839 common shares for gross proceeds of $18,621,498 to fund working capital, global growth initiatives, and preparation for U.S. and EU market entry.